Health Care · Surgical & Medical Instruments & Apparatus

NVCR NovoCure Ltd SEC Filings & Insider Trading Activity 2026

company
CIK 1645113108 filings
Russell 2000

NVCR at a glance

NovoCure Ltd (NVCR, SEC CIK 1645113) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), NovoCure Ltd (NVCR) reported revenue of $655.4 million (up 8.3% from FY2024) and a net loss of $136.2 million. Diluted EPS was -$1.22.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding NovoCure Ltd (NVCR) shares worth $721.2 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Brackmann Christoph on November 9, 2026 of 7,343 shares at $12.86 per share.
  • In the last 90 days, NVCR insiders reported 0 open-market purchases ($0) and 3 open-market sales ($143K) on Form 4, a net sale of $143K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$655.4M
+8.3% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$143K
13F holders
30 funds
$721.2M · +1 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications
  • Geopolitical risk from Greater China market reliance on Zai partnership for development and commercialization
  • Production dependency on third-party manufacturers for sufficient quality and quantity of Products
  • Competition risk from alternative therapies impacting market acceptance despite FDA and CE approvals
  • Historical substantial operating losses with intermittent profits; ongoing high commercialization and R&D expenses

Management Discussion & Analysis

  • Revenue and profitability details not provided in the provided MD&A excerpt
  • Cash flow, capital allocation, and buybacks or dividends details absent
  • Forward-looking guidance or emerging risks not mentioned in the excerpt

Business Overview

  • Core business model: Commercialization of TTFields therapy devices (Optune Gio, Lua, Pax) delivering electric fields to kill cancer cells for solid tumor cancers
  • New emphasis on brain metastases from NSCLC with September 2025 Phase 3 METIS trial showing 28% lower risk of intracranial progression; Optune Mya PMA submitted, FDA review ongoing
  • Strategic expansion to pancreatic cancer with 2026 FDA approval of Optune Pax based on PANOVA-3 trial; survival improved to 16.2 vs 14.2 months (p=0.039)
  • Sales force grew to 217 globally as of December 2025; estimated 8,200 GBM, 30,000 NSCLC, 15,000 pancreatic cancer patients in U.S. eligible and seeking treatment in 2026
  • Unusual milestone: simultaneous regulatory progress with multiple devices; PMA filing acceptance for brain metastases (Optune Mya) and first U.S. approval for pancreatic cancer device Optune Pax

AI summary of the NVCR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors disclosed in the 2025 10-K
  • Carried-forward risks include regulatory, clinical, commercial, operational, and financial uncertainties
  • No new or materially updated risk identified in the quarter

Management Discussion & Analysis

  • Quarterly revenue $193.4M, up 16% YoY from $167.2M, driven by 19% global active-patient growth
  • Gross margin 77% vs 73% YoY, with Optune Lua revenue $8.2M and Optune Pax revenue $3.7M
  • Optune Pax fastest-growing product, $3.7M revenue vs $0.0M YoY; Optune Gio active patients 4,729
  • Cash, equivalents and short-term investments $463.5M, up $15.8M from December 31, 2025
  • Nine-month operating cash flow $17.3M vs $(31.0)M; tariff volatility and rising launch expenses remain headwinds

AI summary of the NVCR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from non-small cell lung cancer
  • Regulatory rejection reflects uncertainty over clinical benefit, not safety concerns

Item EX-99.1: Item EX-99.1

  • FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from NSCLC after stereotactic radiation
  • FDA cited uncertainty about clinical benefit, not safety concerns
Filed Oct 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $193.4M, up 16% YoY, driven by 19% global active-patient growth to 5,260
  • Gross margin 77% vs 73%, while adjusted EBITDA reached $15.7M and net loss narrowed to $10.4M
Filed Oct 1, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Japan MHLW approval expands Optune Pax® into unresectable locally advanced pancreatic cancer
  • Approval covers adult patients receiving gemcitabine and nab-paclitaxel

AI summaries of NVCR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NVCR

Don't miss the next NVCR filing

  • Alerts as it files. A push when NVCR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NVCR, by share count.
  • Ask anything. An AI agent that reads every NVCR filing and answers with sources.

NVCR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Brackmann ChristophSellNov 9, 2026$12.86
Paravasthu MukundSellNov 9, 2026$12.86
Puri Michal NathSellNov 2, 2026$13.24
Leonard Frank XAJun 30, 2026$11.15
Ben Arye BarakAJun 30, 2026$11.15
Danziger AsafAJun 30, 2026$11.15
Puri Michal NathAJun 30, 2026$11.15
Leonard Frank XSellJun 4, 2026$17.93

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$509.3M$605.2M$655.4M
Gross Profit-$468.0M$488.5M
Operating Income--$170.5M-$153.8M
Net Income--$168.6M-$136.2M
Gross Margin-77.3%74.5%
Op. Margin--28.2%-23.5%
Net Margin--27.9%-20.8%
Balance Sheet
Total Assets-$1.2B$804.3M
Equity$362.5M$360.2M$340.5M
ROE--46.8%-40.0%
Per Share
EPS-$-1.56$-1.22
Cash Flow
Operating CF--$26.4M-$49.0M
CapEx-$42.9M$26.6M

Source: XBRL data in NovoCure Ltd (NVCR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NVCR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NVCR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$721.2M
Q2 202629$961.5M
Q1 202628$638.2M
Q4 202526$749.9M
Q3 202527$681.3M
Q2 202529$931.9M
Q1 202527$654.9M
Q4 202427$1.06B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 223 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NVCR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
4Nov 12, 2026--
8-KNov 9, 2026Analysis-
4Nov 4, 2026--
8-KOct 29, 2026Analysis-
10-QOct 29, 2026Analysis
8-KOct 1, 2026Analysis-
8-KSep 9, 2026Analysis-
8-KSep 1, 2026Analysis-
8-KJul 23, 2026Analysis-
10-QJul 23, 2026Analysis
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
8-KJun 30, 2026Analysis-
8-KJun 18, 2026Analysis-
4Jun 5, 2026-
8-KJun 5, 2026Analysis
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-

Related Health Care companies

All Health Care →

NVCR SEC filings: frequently asked questions

Are NVCR insiders buying or selling?

In the last 90 days, NovoCure Ltd (NVCR) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $142,786 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold NVCR stock?

As of September 30, 2026, the largest NovoCure Ltd (NVCR) holders among the 13F filers tracked by SignalX were BlackRock ($189.2 million), Vanguard Portfolio Management LLC ($103.6 million), Vanguard Capital Management LLC ($78.5 million), Morgan Stanley ($74.9 million), State Street Corp ($46.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NVCR's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), NovoCure Ltd (NVCR) reported revenue of $655.4 million (up 8.3% from FY2024) and a net loss of $136.2 million. Diluted EPS was -$1.22. The figures come from the XBRL data in the 10-K.

What are the main risks in NVCR's latest 10-K?

In the 10-K filed February 26, 2026, NovoCure Ltd (NVCR) flagged: FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications. Geopolitical risk from Greater China market reliance on Zai partnership for development and commercialization. (AI summary of the Risk Factors section.)

What did NVCR report in its latest 8-K?

NovoCure Ltd (NVCR) filed an 8-K on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure). FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from non-small cell lung cancer.

What are the latest NVCR SEC filings?

NovoCure Ltd (NVCR) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 12, 2026.

What is NVCR's SEC CIK number?

NovoCure Ltd (NVCR)'s SEC Central Index Key (CIK) is 1645113. EDGAR lists every NVCR filing under that number.

Ask anything about NVCR

The research agent reads NVCR's filings, financials, insider trades and 13F holders, then answers with sources.